HCW BiologicsHCWB -7.62%39 PS Ratio is 0.85 as of Jun. 28, 2026, which is 94% below its 10-year median of 14.23. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $7.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 936 Biotechnology companies, HCW Biologics ranks better than 93.8% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, HCW Biologics's share price is $1.04.
HCW Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.23. Hence, HCW Biologics's PS Ratio for today is 0.85.
The historical rank and industry rank for HCW Biologics's PS Ratio or its related term are showing as below:
HCWB'
s PS Ratio Range Over the Past 10 Years
Min: 0.22 Med: 14.23 Max: 60
Current: 0.85
During the past 7 years, HCW Biologics's highest PS Ratio was 60.00. The lowest was 0.22. And the median was 14.23.
HCWB's PS Ratio is ranked better than 93.8% of 936
companies
in the Biotechnology industry
Industry Median: 9.155
vs HCWB: 0.85
HCW Biologics Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of HCW Biologics was -17.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -84.90% per year.
During the past 7 years, HCW Biologics's highest 3-Year average Revenue per Share Growth Rate was -18.00% per year. The lowest was -84.90% per year. And the median was -51.45% per year.
Back to Basics: PS Ratio
HCW Biologics (NAS:HCWB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
HCW Biologics PS Ratio Related Terms
HCW Biologics PS Ratio Historical Data
* Premium members only.
The historical data trend for HCW Biologics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HCW Biologics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's PS Ratio distribution charts can be found below:
* The bar in red indicates where HCW Biologics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
HCW Biologics's Share Price of today is $1.04. HCW Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.23.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
HCW Biologics (HCWB) has a PS Ratio of 0.85 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on HCW Biologics and its competitors. This is 94% below median its historical median of 14.23. Over the past decade, HCW Biologics' PS Ratio has ranged from 0.22 to 60.00. According to the industry distribution chart, HCW Biologics ranks #58 out of 936 companies in the Biotechnology industry, placing it in the top 6.2%.
Is HCW Biologics' PS Ratio too high?
HCW Biologics' current PS Ratio of 0.85 is 94% below median its 10-year median of 14.23. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 60.00. The Biotechnology industry median PS Ratio is 9.16. HCW Biologics' value of 0.85 is 90.7% below this industry median. Based on the distribution chart, HCW Biologics ranks #58 out of 936 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' PS Ratio compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #58 out of 936 companies for PS Ratio. This places HCW Biologics in the top 6% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.16. HCW Biologics' value of 0.85 is 90.7% below this benchmark. Historically, HCW Biologics' own PS Ratio has ranged from 0.22 to 60.00 over the past decade. While the company's 10-year median is 14.23 vs. the industry median of 9.16, HCW Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.16, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current PS Ratio of 0.85 is 90.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current PS Ratio is 0.85, which is 94% below median its own 10-year median of 14.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.04 — trading 85.7% below its estimated fair value. The current PS Ratio is 0.85, which is 94% below median its 10-year median of 14.23 and 90.7% below the Biotechnology industry median of 9.16. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For HCW Biologics (HCWB), the current PS Ratio is 0.85 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $1.04 is trading 85.7% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
PS Ratio: 0.85 (94% below median its 10-year median of 14.23)
GF Value™: $7.29 vs. price of $1.04 (85.7% below fair value)
Industry Position: 90.7% below the Biotechnology median (#58 of 936)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
